NASDAQ: IPSC

Century Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for IPSC. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 04:44 UTC.

What Century Therapeutics, Inc. does

This biotechnology company develops off-the-shelf cell therapies using induced pluripotent stem cells, or iPSCs, to treat autoimmune diseases including type 1 diabetes and cancer. The company uses CRISPR gene editing and proprietary Allo-Evasion technology to create allogeneic cell products derived from healthy donors that can be manufactured in advance and used for any patient. The company is advancing several programs including a beta islet program for type 1 diabetes and CD4+/CD8+ T cell and natural killer cell therapies for various diseases.

Summarized from Century Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-16
Return on equity	-6.03%

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-15

2026-09-15See RemarksSale-2,587$5.0K
2026-09-15SVP Finance & OperationsSale-1,658$3.2K
2026-09-15President and CEOTax withholding-13,850$26.9K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

RA CAPITAL MANAGEMENT, L.P.17,754,430$43.50M0.0%
TCG Crossover Management, LLC17,754,430$43.40M0.0%
Versant Venture Management, LLC12,166,109$29.81M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-09-09Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersJoseph TruittAuthoritativeSEC 8-K →
2025-08-14Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-07-07Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
globenewswire.com2026-10-02
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet
seekingalpha.com2026-09-30NEG
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Century Therapeutics, Inc. do?

This biotechnology company develops off-the-shelf cell therapies using induced pluripotent stem cells, or iPSCs, to treat autoimmune diseases including type 1 diabetes and cancer.

When did IPSC last file with the SEC?

Century Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-16. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:44 UTC. This page is also available as JSON at /api/data?ticker=IPSC and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IPSC and 5,000+ tickers.

Create a free account — keep IPSC

For your agent

GET /api/data?ticker=IPSC

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt